ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

Stock Information for ObsEva SA

Loading

Please wait while we load your information from QuoteMedia.